‹ ›
MYP_139665
← PREVIOUS NEXT → BACK
Basic Information
VMI5
Anticancer
Anticancer ▸ Tumor Homing Peptide
Antimicrobial
Antiviral
Antiviral ▸ Anti-HIV ▸ Anti-HIV-1
Antiviral ▸ Antiviral mechanism ▸ Viral entry inhibition ▸ Entry inhibitor
Antiviral ▸ Antiviral mechanism ▸ Viral replication inhibition
Delivery / Targeting ▸ Drug delivery vehicle
Enzyme modulation ▸ Enzyme inhibition ▸ Vif multimerization inhibitor
Standard
12 amino acids
C53H92N16O16S
Standard
Sequence
SVSVGMKPSPRP
Physicochemical Analysis
1241.46 Da
11.00
1.46
1.25
0.1216
-0.47
0.42
-0.08
58.24
48.33
0.0000
0.00
0.00
The radar chart summarizes major physicochemical dimensions for quick comparison, while exact numerical values remain listed on the left.
Residue Composition
Amino Acid Composition
Chemical Descriptors
505.66
-6.68
17.0
19.0
36.0
86.0
3.0
11.0
Structural Visualization
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber in the current view mode. Use the buttons to zoom.
2D CHEMICAL STRUCTURE
Drag to move
Drag to move. Use the buttons to zoom.
Experimental Records
RECORD: Rec_0153825 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Vif multimerization inhibitor
H9
Qualitative inhibition
PaperPotent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. PMID12480936 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12480936/
RECORD: Rec_0242580 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Protein-derived synthetic peptide
32630
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antiviral Anti-HIV-1 Replication inhibition
HIV-1
Mammalian: 1.9 h; Yeast: >20 h; E. coli: >10 h
PaperPotent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus type 1 (HIV-1) Vif proteins. | Yang B, Gao L, Li L, Lu Z, Fan X, Patel CA, Pomerantz RJ, DuBois GC, Zhang H. | J Biol Chem. 2003 Feb 21;278(8):6596-602. | DOI:10.1074/jbc.M210164200 | PMID:12480936 PMID12480936 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/12480936/
RECORD: Rec_0280819 VERIFIED: NO
Provenance & Taxonomy
not reported [other]
Structure & Mods
topology not specified [Not included yet]
stereochemistry not specified [Other]
Bio-Activity Profile
Anticancer
RECORD: Rec_0282460 VERIFIED: YES
Provenance & Taxonomy
not reported [other]
Structure & Mods
linear peptide [Linear]
canonical L-amino-acid peptide [L]
None
None
Bio-Activity Profile
Antimicrobial Antiviral Drug Delivery Vehicle Tumor Homing Peptide
PaperHIPdb: a database of experimentally validated HIV inhibiting peptides PMID23359817 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/23359817/
RECORD: Rec_0325287 VERIFIED: YES
Provenance & Taxonomy
synthetic construct [Synthetic]
Library-derived peptide
32630
Structure & Mods
synthetic linear peptide [Linear]
canonical L-amino-acid peptide [L]
Bio-Activity Profile
Antiviral Entry inhibitor
Hepatitis C virus (HCV E2); Huh7.5
RT-PCR
PaperSelection of peptides binding to HCV e2 and inhibiting viral infectivity. | Hong HW, Lee SW, Myung H. | J Microbiol Biotechnol. 2010 | PMID:21193836 PMID21193836 Evidence URLhttps://pubmed.ncbi.nlm.nih.gov/21193836/